One in Eight Cancer Cases Linked to Infections, Study Finds

A new analysis of global cancer patterns has found that infections are responsible for roughly one in every eight cancer diagnoses worldwide—a proportion large enough to reshape how public health officials think about cancer prevention. The finding underscores a simple but consequential truth: some of the most common cancers are not inevitable. They are caused by pathogens that can be detected, treated, or prevented through vaccination.

The research identifies five specific infections as the primary culprits behind this disease burden. These five pathogens together account for more than two million new cancer cases each year across the globe. The infections in question are human papillomavirus, hepatitis B virus, hepatitis C virus, Helicobacter pylori bacteria, and Epstein-Barr virus. Each one triggers cancer through different mechanisms—some by causing chronic inflammation, others by directly damaging cellular DNA—but all share a common feature: their cancer-causing potential can be substantially reduced through existing medical interventions.

The scale of this burden becomes clearer when placed in context. Two million cases annually represents a staggering toll of preventable disease. These are not rare cancers or exotic syndromes. Cervical cancer, driven largely by HPV infection, remains one of the leading cancer deaths among women in low- and middle-income countries. Liver cancer, linked to chronic hepatitis B and C infection, kills hundreds of thousands of people each year. Stomach cancer caused by H. pylori affects millions. The infections are common; the cancers they produce are common; and yet many of these cases could be averted.

The implications for public health strategy are substantial. Vaccination programs already exist for HPV and hepatitis B, and they have proven effective at preventing infection and, by extension, the cancers that follow. Yet vaccination coverage remains uneven across the world. In wealthy nations, HPV vaccination rates among adolescents have climbed steadily, and cervical cancer incidence has fallen as a result. In many lower-income countries, however, access to these vaccines remains limited or nonexistent. The same disparity applies to hepatitis B vaccination, which has been part of childhood immunization schedules in developed countries for decades but is less universally available elsewhere.

Beyond vaccination, screening and treatment of existing infections offer another avenue for prevention. Hepatitis C, once a death sentence, can now be cured with antiviral medications in the vast majority of cases—yet many people infected with the virus do not know their status and cannot access treatment. H. pylori can be detected and eliminated with antibiotics, preventing the progression to stomach cancer. Early detection of cervical precancers through screening allows for intervention before malignancy develops. These tools exist. The barrier is often not scientific but logistical and economic.

Experts emphasize that the findings should catalyze action at multiple levels. Expanding vaccination programs in regions where coverage remains low could prevent hundreds of thousands of cancer cases over the coming decades. Improving access to screening and treatment for those already infected could prevent progression to cancer in millions more. The research suggests that a substantial portion of the global cancer burden—one in eight cases—is not a fixed feature of human biology but a consequence of preventable infections. That distinction matters. It means that cancer prevention is not only about lifestyle changes or early detection of existing disease. It means that some cancers can be stopped before they start, through interventions that are already known to work.